Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05670366
Other study ID # S64550
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 26, 2022
Est. completion date March 1, 2023

Study information

Verified date December 2022
Source Universitaire Ziekenhuizen KU Leuven
Contact Pieter Gillard, MD, PhD
Phone 016 340615
Email pieter.gillard@uzleuven.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Every person with type 1 diabetes needs personalized advice to integrate physical activity into daily diabetes management. The purpose of this study is to collect data on food intake, physical activity, glucose levels and insulin delivery from people with type 1 diabetes who are physically active. At least 25 people with type 1 diabetes will be asked to perform 25 sports activities of at least half an hour, wear an activity tracker (day and night) and chest strap (during sports activities), and log data on food intake, periods and type of physical activity, and feelings (e.g., sick, stress) in a diary app. Diabetes data such as insulin administration and sensor data will be collected through diabetes management platforms. The primary endpoint involves a database containing data on glucose, insulin administration, physical activity, and food intake of people with type 1 diabetes for statistical analyses and visualizations regarding the relationship between physical activity and blood glucose response.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date March 1, 2023
Est. primary completion date March 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Signed informed consent - 18-80 years old - Type 1 diabetes =1 year - Using a CGM for more than 6 months - Using insulin (insulin pens, insulin pumps or hybrid closed-loop systems) to manage glycaemia for more than 6 months - No use of adjunctive therapies, such as SGLT2-inhibitors or GLP-1 analogues - No known diabetic gastroparesis - HbA1c of the last two diabetes consultations are both <10% - Being physically active at least twice a week on two separate days for 30 consecutive minutes Exclusion Criteria: - Age <18 years or >80 years - People with type 2 diabetes, people with secondary diabetes - Begin treatment with insulin (insulin pens, insulin pumps or hybrid closed-loop systems) less than 6 months before inclusion - Not using CGM prior to inclusion - Known diabetic gastroparesis - HbA1c > 10% during one of the last two diabetes consultations - Not willing to use an activity tracker, the diary app or the food app - Not being physically active on a regular basis

Study Design


Intervention

Device:
Activity tracker and chest strap
During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
Diary app
During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.

Locations

Country Name City State
Belgium UZ Leuven Leuven

Sponsors (2)

Lead Sponsor Collaborator
prof dr Pieter Gillard University Colleges Leuven Limburg

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Database which contains insulin data (insulin dose over time) retrieved from diabetes management platforms. Through study completion (after 25 sport activities), an average of 6 weeks
Primary Database which contains glucose data (glycemic values over time) retrieved from diabetes management platforms. Through study completion (after 25 sport activities), an average of 6 weeks
Primary Database which contains physical activity data (type of activity) retrieved from the activity tracker and chest strap. Through study completion (after 25 sport activities), an average of 6 weeks
Primary Database which contains physical activity data (intensity of activity) retrieved from the activity tracker and chest strap. Through study completion (after 25 sport activities), an average of 6 weeks
Primary Database which contains physical activity data (duration of activity) retrieved from the activity tracker and chest strap. Through study completion (after 25 sport activities), an average of 6 weeks
Primary Database which contains food intake data (timing of food) retrieved from the diary app. Through study completion (after 25 sport activities), an average of 6 weeks
Primary Database which contains food intake data (amount of food in grams) retrieved from the diary app. Through study completion (after 25 sport activities), an average of 6 weeks
Primary Database which contains food intake data (type of food) retrieved from the diary app. Through study completion (after 25 sport activities), an average of 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4